

**Table S1.** Comparison of baseline characteristics between all Quartiles (1–4).

Variable	Quartile 1 (n = 60)	Quartile 2 (n = 60)	Quartile 3 (n = 60)	Quartile 4 (n = 59)
Age, years ± SD	79 ± 10	78 ± 9	78 ± 10	76 ± 9
Body Mass Index, kg/m <sup>2</sup> ± SD	30.8 ± 4.6	30.6 ± 6.6	31.2 ± 5.8	31.0 ± 5.1
Diabetes Mellitus	40.7%	44.1%	48.3%	39.0%
Hypertension	91.5%	88.1%	90.0%	84.7%
Systolic Blood Pressure, mmHg ± SD	131 ± 21	130 ± 28	132 ± 20	129 ± 20
Diastolic Blood Pressure, mmHg ± SD	74 ± 11	74 ± 15	75 ± 13	73 ± 12
Dyslipidemia	71.1%	83.1%	70.0%	81.4%
LDL Cholesterol, mg/dL ± SD	116 ± 46	94 ± 26	105 ± 38	94 ± 26
Prior Myocardial Infarction	41.7%	49.2%	44.1%	49.2%
Prior Coronary Artery Bypass Graft	26.7%	33.3%	28.3%	23.7%
Prior Percutaneous Coronary Intervention	28.3%	35.0%	38.3%	35.6%
Chronic Kidney Disease	41.4%	44.8%	41.7%	44.1%
Serum Creatinine, mg/dL ± SD	1.5 ± 0.8	1.5 ± 0.6	1.6 ± 0.6	1.4 ± 0.5
History of Tobacco Use	83.3%	78.0%	83.3%	81.4%
Current Tobacco Use	16.9%	15.3%	8.5%	18.6%
Allopurinol Use	36.7%	20.3%	33.3%	18.6%
Serum Uric Acid, mg/dL ± SD	8.2 ± 2.0	8.9 ± 2.0	8.7 ± 2.3	8.9 ± 2.0
NSAID Use	38.3%	30.0%	28.3%	23.7%
Aspirin Use	55.0%	63.3%	58.3%	62.7%
Statin Use	53.3%	65.0%	66.7%	74.6%
ACE inhibitor Use	38.3%	61.7%	53.3%	55.9%
β-blocker Use	70.0%	63.3%	78.3%	72.9%
Any Antihypertensive Use	55.0%	70.0%	86.7%	69.5%
Mean Daily Colchicine Dose, mg ± SD	0.73 ± 0.31	0.78 ± 0.26	0.66 ± 0.18	0.69 ± 0.22
Time on Colchicine, % of observation period ± SD	11.4 ± 4.9	31.3 ± 7.4	56.6 ± 7.8	88.5 ± 9.9

Continuous data are shown as mean ± standard deviation. Categorical data are shown as a percentage of the total subgroup. SD, standard deviation; LDL, low-density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; ACE, angiotensin-converting enzyme.

**Table S2.** Total Major Adverse Cardiovascular Events and Component Events in Colchicine Users and Nonusers.

Major Adverse Cardiovascular Event	Nonusers (n = 116)	Colchicine Users (n = 239)
Total First Major Adverse Cardiovascular Events	17	43
Myocardial Infarction	7	24
Coronary Artery Bypass Graft	3	9
Cerebrovascular Accident	6	6
All-cause mortality	2	8

The Total First Major Adverse Cardiovascular Events row displays the number of patients experiencing first-observed MACE within each group. Subsequent events for each individual patient were censored for logistic regression and Kaplan Meier analysis.

**Table S3.** Total Major Adverse Cardiovascular Events and Component Events in Each Colchicine-use Quartile.

Major Adverse Cardiovascular Event	Quartile 1 (n = 60)	Quartile 2 (n = 60)	Quartile 3 (n = 60)	Quartile 4 (n = 59)
Total First Major Adverse Cardiovascular Events	10	15	13	5
Myocardial Infarction	7	7	7	3
Coronary Artery Bypass Graft	2	3	3	1
Cerebrovascular Accident	0	2	3	1
All-cause mortality	2	5	1	0

The Total First Major Adverse Cardiovascular Events row displays the number of patients experiencing first-observed MACE within each quartile. Subsequent events for each individual patient were censored for logistic regression and Kaplan Meier analysis.